Diabetes management technology pioneer Beta Bionics has achieved another milestone, successfully amassing $100 million in its latest Series D equity funding round. The recent accomplishment surpasses ...
Beta Bionics Inc. was born out of a father’s desire to improve his son’s quality of life following a diabetes diagnosis. Today, 10 years after its founding, it’s now a publicly traded company. The ...
Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company's first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales ...
IRVINE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that near ...
Beta Bionics, Inc. ((BBNX)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
While other automated dosing algorithms typically require a doctor to program certain starting parameters, Beta Bionics’ iLet Bionic Pancreas needs only a user’s body weight to begin calculating ...
Beta Bionics Inc., which makes a “bionic pancreas,” has secured $60 million in a Series E funding round led by new investor Wellington Management. The funding fuels Beta Bionics’ continued ...
Beta Bionics Inc. received U.S. FDA clearance for its Ilet Bionic Pancreas, an automated insulin-delivery (AID) system that calculates 100% of insulin doses without requiring carb counting or manual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results